Search

everythinglearnresearchcommunity

for

Search:↓

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Etanercept effectively treated a severe skin condition when other treatments failed.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.

Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Methotrexate injection site reactions are rare but can be managed by changing injection sites and using topical treatments.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.